Fracturas múltiples y consumo inusual de pastillas Juanola(R) de regaliz / Multiple fractures and unusual consumption of licorice pastillas Juanola(R)

El regaliz (Glycyrrhiza glabra) se ha considerado una planta medicinal desde hace miles de años, y actualmente se utiliza en multitud de preparados por su sabor, poder endulzante y efecto antiinflamatorio. No está exento de efectos secundarios, entre ellos, la hipertensión por su efecto mineralcorticoide. Además, los flavonoides presentes en el extracto de regaliz producen un aumento de la hormona paratiroidea (PTH) y de los niveles de calcio en la orina. Presentamos un caso de una mujer de 60 años con fracturas múltiples asociadas a un consumo inusual y exagerado de pastillas Juanola® (PJ®), producto a base de extracto de regaliz

Licorice (Glycyrrhiza glabra) has been considered a medicinal plant for thousands of years, and it is included in several compounds for its flavor, sweetener and anti-inflammatory properties. It is not free of side effects, including high blood pressure due to its mineralocorticoid effect. In addition, there are flavonoids in licorice extract which increase serum parathyroid hormone (PTH) and urinary calcium levels. We report a case of a 60-year-old woman with multiple bone fractures associated with an unusual and exaggerate consumption of pastillas Juanola (PJ), product based on licorice extract

Xantotriquia probablemente iatrogénica / Probable Iatrogenic Xanthotrichia

No disponible

Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.

WHAT IS KNOWN AND OBJECTIVE: Stiff-person syndrome (SPS) is an uncommon and disabling disorder characterized by progressive rigidity and episodic painful spasms involving axial and limb musculature. SPS treatment is mostly based on benzodiazepines, baclofen, immunosuppressants and intravenous immunoglobulin. Cannabis derivatives [tetrahydrocannabinol (THC) and cannabidiol (CBD)] are available as an oromucosal spray (Sativex(®)), indicated as add-on treatment, for symptom improvement in patients with moderate to severe spasticity because of multiple sclerosis (MS). Our objective is to report a case of seronegative SPS successfully treated with THC-CBD oromucosal spray. CASE SUMMARY: We report a case of a 40-year-old man presenting with progressive muscle stiffness and intermittent spasms for 6-years. The diagnosis of stiff-person syndrome was based on the clinical features and neuroelectrophysiologic findings of continuous motor unit activity. Glutamic acid decarboxylase autoantibodies was absent in our patient, in both serum and cerebrospinal fluid (CSF). Cannabis derivatives oromucosal spray was introduced after a series of unsatisfactory traditional medical treatments. After 14 months treated with THC-CBD oromucosal spray, improvement was verified in the eight dimensions of the scale of SF-36 quality of life questionnaire. WHAT IS NEW AND CONCLUSION: Clinical experience with cannabis derivatives in patients with multiple sclerosis is accumulating steadily, but there is no current literature about its efficacy for SPS. Because MS and SPS share some neurological symptoms such as spasticity and rigidity, it is thought that THC-CBC can be an option for SPS patient. Our case report suggests that THC-CBD oromucosal spray is an alternative treatment for patients with refractory SPS, and further validation is appropriate.